Ocular Therapeutix (OCUL) Set to Announce Quarterly Earnings on Thursday

Ocular Therapeutix (NASDAQ:OCUL) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect Ocular Therapeutix to post earnings of ($0.23) per share for the quarter.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.04). The firm had revenue of $16.40 million for the quarter, compared to the consensus estimate of $15.85 million. Ocular Therapeutix had a negative return on equity of 52.75% and a negative net margin of 226.46%. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) earnings per share. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ocular Therapeutix Stock Up 3.5 %

Shares of NASDAQ OCUL opened at $10.94 on Thursday. Ocular Therapeutix has a 1 year low of $2.00 and a 1 year high of $11.77. The firm’s 50-day moving average is $9.61 and its 200-day moving average is $7.74. The company has a current ratio of 16.64, a quick ratio of 16.55 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.71 billion, a PE ratio of -8.10 and a beta of 1.26.

Wall Street Analysts Forecast Growth

OCUL has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. Scotiabank initiated coverage on Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price target on the stock. Finally, Robert W. Baird dropped their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.